Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people.

Daniele SantiG SpaggiariL MarinelliM CaccianiS ScipioA BichiriA ProfetaA R M GranataM SimoniF LanfrancoC ManieriE GhigoG Motta

Published in: Journal of endocrinological investigation (2023)

Our real-world clinical study shows that transgender AFAB achieve hormone target earlier and more frequently in comparison to transgender AMAB individuals. Therefore, transgender AMAB people may require more frequent check-ups in order to tailor feminizing GAHT and increase therapeutic adherence.

Keyphrases

hiv testing
men who have sex with men
type diabetes
mental health
clinical trial
skeletal muscle
hepatitis c virus
insulin resistance
human immunodeficiency virus
combination therapy
double blind